No statistically significant quality difference was shown between significant and nonsignificant studies neither for the global score (median: 51.50 vs 53.83%, P=0.90), neither for the four subgroups scores.
The most recent study neither adjusted for breast-feeding nor for additional prenatal methylmercury (MeHg) exposure from maternal fish consumption, but they attributed the conflicting outcomes to chance (Thompson et al. 2007).
In addition, the study neither allows for the investigation of additional explanations for nonadherence nor analyzes expected change in utilization stemming from interventions.
Concomitant treatment with H2 receptor blockers, proton pump inhibitors, misoprostol, methotrexate, warfarin, analgesics (other than rescue medication) and systemic corticosteroids was not permitted during the study; neither was physiotherapy for the target joint.
In addition, reactions of this kind generally occur in timescales convenient for study, neither too fast nor too slow, and under conditions that are easily manipulated for experimental purposes.
As in the majority of studies, neither of these were available for the UKCCS, where individual reasons for participation could only be indirectly related with the deprivation index.
In this study, neither the "gold" standard for false or true metastases was available.
However, this study neither negates the need for new data from a randomized controlled trial nor contradicts the current UK National Institute for Health and Clinical Excellence guidelines for use of DrotAA.
While the study populations may not be necessarily comparable, in our study, neither the effect estimates for daily exposures nor any exposure-time interactions were statistically significant, which may be a further indication that any exposure effects may accumulate over longer time windows than were assessed here.
